GENB (Generate Biomedicines) EBITDA Margin %: -653.71% (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines EBITDA Margin %?

Generate Biomedicines GENB +2.18% 6 EBITDA Margin % is -653.71% as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Generate Biomedicines ranks worse than 74.95% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Generate Biomedicines's EBITDA for the six months ended in Dec. 2025 was $-208.49 Mil. Generate Biomedicines's Revenue for the six months ended in Dec. 2025 was $31.89 Mil. Therefore, Generate Biomedicines's EBITDA margin for the quarter that ended in Dec. 2025 was -653.71%.

Generate Biomedicines  (NAS:GENB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Generate Biomedicines EBITDA Margin % Related Terms

Generate Biomedicines EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines EBITDA Margin % Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
EBITDA Margin %
-800.16 -653.71

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
EBITDA Margin % -800.16 -653.71

GENB vs PVLA, SLBT, NKTR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Generate Biomedicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generate Biomedicines EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's EBITDA Margin % falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Generate Biomedicines's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-208.488/31.893
=-653.71 %

Generate Biomedicines's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-208.488/31.893
=-653.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -653.71% mean?
Generate Biomedicines (GENB) has a EBITDA Margin % of -653.71% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #706 out of 942 companies in the Biotechnology industry, placing it in the top 74.9%.
Is Generate Biomedicines' EBITDA Margin % too high?
Generate Biomedicines' current EBITDA Margin % is -653.71%. Based on the distribution chart, Generate Biomedicines ranks #706 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' EBITDA Margin % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #706 out of 942 companies for EBITDA Margin %. This places Generate Biomedicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current EBITDA Margin % is -653.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current EBITDA Margin % of -653.71%. The current EBITDA Margin % is -653.71%. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current EBITDA Margin % is -653.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price